UBS Group
HRTX icon

UBS Group’s Heron Therapeutics HRTX Stock Holding History

UBS Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-700
Closed -$17K – 8447
2015
Q3 		$17K Sell
700
-15,000
-96% -$500K ﹤0.01% 6849
2015
Q2 		$489K Buy
+15,700
New +$295K ﹤0.01% 4152

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

UBS Group's HRTX Position: Q2 2026 in Review

UBS Group increased its Heron Therapeutics (HRTX) stake by 31% in Q2 2026, buying an estimated $570K and bringing the position to 2,997,073 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #5517.

UBS Group first reported a position in HRTX in Q4 2014 and has held it in 47 quarters since. The position peaked at $9.38M in Q4 2015. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • UBS Group held 2,997,073 shares of Heron Therapeutics worth $1.28M as of Q2 2026.
  • UBS Group bought 711,190 Heron Therapeutics shares in Q2 2026, an estimated $570K.
  • Heron Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5517 holding.
  • UBS Group first reported a position in Heron Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Heron Therapeutics position peaked at $9.38M in Q4 2015.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.